Larimar to kick off higher dose of lead rare disease drug, initiate OLE trial

The FDA gave Larimar Therapeutics the go-ahead to introduce a higher dose of its Friedreich’s ataxia treatment in a Phase II study.

The biotech announced Tuesday that the company can now use 50 mg doses of its lead drug, also known as CTI-1601, in the study. The 12 to 15 adult patients Larimar plans to enroll in that cohort will be randomized to either the drug or placebo, then dosed every day for the first two weeks.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Ascidian Therapeutics raises $40m to advance drug development

Ascidian’s lead programme is an RNA exon editor, which can potentially prevent the progression of ABCA4 retinopathies. Credit: fizkes / Shutterstock.com. Ascidian Therapeutics has raised $40m

November 9, 2023

Why Sanofi got shellacked

Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion consumer health division, which is exploring over-the-counter moves for the

October 27, 2023

COVID-19 pandemic has increased mental health burden on family and friends of patients

Family members and close friends of people with COVID-19 have elevated symptoms of depression and anxiety, a study from Karolinska Institutet published in The Lancet

September 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.